In line with this concept, CXCR4 antagonists were successfully used to block interactions between CLL and stromal cells and to mobilize CLL cells from their protective microenvironments, becoming thus accessible to conventional drugs [180]. This evidence concerns the gene CXCR4 and B-cell chronic lymphocytic leukemia.